Learning from the North American Psychedelics Market: is Europe Following in its Footsteps or Forging its Own Path?

Alternative health is a rising trend across all corners of the world; the global psychedelics industry is currently expected to be worth over US$100 billion, with the potential to save US$1 trillion on lost productivity, disrupting the ...

Historic Phase 3 MDMA Clinical Trial Shows Success in Chronic PTSD

This week, the Multidisciplinary Association for Psychedelic Studies (MAPS) released findings from a groundbreaking Phase 3 clinical trial that suggest MDMA-assisted therapy will be an effective treatment for severe, chronic ...

Looking Back on the First PSYCH Investor Summit: Europe & Asia

On 21 April 2021, hundreds of attendees from investment, science and healthcare areas attended the PSYCH Investor Summit: Europe & Asia. The concise half-day virtual conference delivered the industry’s most promising opportunities ...

Rick Doblin: On 35 Years of MAPS, Opportunities for Psychedelic Investors and the Path to Creating a Strong Industry

This month, the Multidisciplinary Association for Psychedelic Studies (MAPS) celebrated a milestone: 35 years of research and advocacy of psychedelics. Founded in 1986, the US-based non-profit research and educational organisation has ...

Psychedelics Apps: A New Wave in Data Collection & User Experience

The recent surge of interest in psychedelic medicine and research efforts has given rise to a truly 21st-century advent: psychedelic mobile apps and data tools.  From bonafide research tools to psychedelic simulation platforms, ...